SSY Group Ltd
HKEX:2005
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
SSY Group Ltd
Other Long-Term Assets
SSY Group Ltd
Other Long-Term Assets Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Long-Term Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
S
|
SSY Group Ltd
HKEX:2005
|
Other Long-Term Assets
HK$63m
|
CAGR 3-Years
-19%
|
CAGR 5-Years
-15%
|
CAGR 10-Years
-14%
|
|
|
Regencell Bioscience Holdings Ltd
NASDAQ:RGC
|
Other Long-Term Assets
$93k
|
CAGR 3-Years
-5%
|
CAGR 5-Years
36%
|
CAGR 10-Years
N/A
|
|
|
G
|
Grand Pharmaceutical Group Ltd
HKEX:512
|
Other Long-Term Assets
HK$1.1B
|
CAGR 3-Years
1%
|
CAGR 5-Years
28%
|
CAGR 10-Years
13%
|
|
|
Sino Biopharmaceutical Ltd
HKEX:1177
|
Other Long-Term Assets
¥562.4m
|
CAGR 3-Years
-18%
|
CAGR 5-Years
-32%
|
CAGR 10-Years
0%
|
|
|
C
|
China Resources Pharmaceutical Group Ltd
HKEX:3320
|
Other Long-Term Assets
HK$7.2B
|
CAGR 3-Years
10%
|
CAGR 5-Years
17%
|
CAGR 10-Years
N/A
|
|
|
H
|
HUTCHMED (China) Ltd
HKEX:13
|
Other Long-Term Assets
$32.7m
|
CAGR 3-Years
2%
|
CAGR 5-Years
9%
|
CAGR 10-Years
17%
|
|
SSY Group Ltd
Glance View
SSY Group Ltd. stands out as a significant player in the Chinese pharmaceutical industry, seamlessly interweaving its intricate supply chain operations with its robust manufacturing capabilities. Founded in 1994, the company has its roots in the scenic Hebei Province and has evolved into a powerful force in the realm of injectable pharmaceuticals and oral solutions. The organization primarily operates through its core segment—manufacturing and distributing intravenous infusion solutions. By leveraging cutting-edge technology and adhering to stringent quality standards, SSY Group has managed to capture a sizable share of the domestic market, ensuring a steady stream of revenue. The firm's prowess isn't limited to its pharmaceutical expertise. SSY Group's growth strategy involves a careful blend of organic expansion and strategic acquisitions, which enables it to broaden its product categories and penetrate new regional markets. By offering a wide variety of products ranging from antibiotics to anti-infection drugs, the company adeptly meets diverse healthcare needs while simultaneously driving profitability. Additionally, SSY Group bolsters its financial performance through its involvement in both research and development. By dedicating resources toward innovation, it aspires to maintain its competitive edge, producing high-value products that facilitate sustainable long-term growth. Thus, SSY Group's tightly-knit approach to blending manufacturing excellence with strategic growth initiatives paints a picture of a company adeptly navigating the challenges and opportunities of the healthcare sector.
See Also
What is SSY Group Ltd's Other Long-Term Assets?
Other Long-Term Assets
63m
HKD
Based on the financial report for Dec 31, 2025, SSY Group Ltd's Other Long-Term Assets amounts to 63m HKD.
What is SSY Group Ltd's Other Long-Term Assets growth rate?
Other Long-Term Assets CAGR 10Y
-14%
Over the last year, the Other Long-Term Assets growth was -53%. The average annual Other Long-Term Assets growth rates for SSY Group Ltd have been -19% over the past three years , -15% over the past five years , and -14% over the past ten years .